雌激素保护慢性肾脏病雌鼠免于FGF23诱导的左心室肥厚
在Col4a3敲除慢性肾脏病小鼠模型中,雄性出现进行性BUN和FGF23升高、20周时明显左心室肥厚及22周早死,雌性虽BUN和FGF23升高更早却不发生左心室肥厚且寿命更长。转录组学显示雄性CKD中FGF23的近端靶标是雌激素信号的下游靶点,体外实验表明雌二醇可阻止FGF23诱导的心肌细胞肥大,卵巢切除则触发雌鼠左心室肥厚。
要点
- 慢性肾脏病雌鼠虽FGF23升高更早但不发生左心室肥厚且寿命长于雄鼠
- FGF23在心脏的近端靶标与雌激素信号下游靶点重合
- 雌二醇可阻止FGF23诱导的心肌细胞肥大及钙调磷酸酶活性
核心结论
- 雌激素通过拮抗FGF23的促肥大效应,在慢性肾脏病中发挥女性特异性心脏保护机制。
研究设计与样本
- 研究比较了年龄匹配的野生型与Col4a3敲除小鼠在CKD进展中的矿物质代谢、肾脏和心脏表型,并按性别分开分析。
- 采用转录组学鉴定参与CKD相关左心室肥厚的FGF23近端靶点。
- 在体内及培养的新生小鼠心肌细胞中测试了FGF23与雌二醇的作用。
主要发现
- 与野生型相比,CKD雄鼠BUN和FGF23水平进行性升高,20周时出现明显左心室肥厚,22周时早死。
- CKD雌鼠BUN和FGF23升高更早,但未发生左心室肥厚且寿命长于雄鼠。
- RNA测序显示雄性CKD中鉴定的FGF23近端靶点是雌激素信号的已知下游靶点。
- 体外FGF23诱导雄性和雌性小鼠来源心肌细胞肥大生长,雌二醇共处理可阻止该效应。
- 雌二醇阻止雄性小鼠心脏中FGF23诱导的钙调磷酸酶活性,而卵巢切除触发CKD雌鼠左心室肥厚。
临床怎么用
- 提示在CKD患者中评估心脏肥厚风险时需考虑性别差异及雌激素状态。
- 卵巢切除或绝经后CKD女性可能因雌激素缺乏而丧失对FGF23促肥大效应的拮抗,需关注心脏表型。
局限性
- 研究为小鼠模型及离体细胞实验,结论向人类CKD患者的外推需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fibroblast growth factor 23 (FGF23) contributes to left ventricular hypertrophy (LVH) and mortality in chronic kidney disease (CKD). Males have a higher risk of cardiovascular events than females. The protective effects of estrogen on the heart are well established, but it remains unclear if cardiac FGF23 signaling is modified in females with CKD. METHODS: We studied mineral metabolism, kidney and heart phenotypes of age-matched wild-type (WT) and Col4a3 knockout (Col4a3KO) mice during CKD progression and used transcriptomics to identify proximal targets of FGF23 involved in CKD-associated LVH. Additionally, we tested the effects of FGF23 and estradiol (E2) in vivo and on cultured neonatal mouse cardiomyocytes (NMCMs). All results were separated by sex. RESULTS: Compared to WT, CKD males showed progressive increases in blood urea nitrogen (BUN) and FGF23 levels, overt LVH at 20 weeks, and premature death at 22 weeks. In contrast, CKD females showed earlier increases in BUN and FGF23 levels but did not develop LVH and lived longer than males. RNA sequencing analyses revealed that the proximal targets of FGF23 identified in males with CKD are established downstream targets of estrogen signaling. In vitro, FGF23 induced the hypertrophic growth of NMCMs isolated from male and female mice and E2 co-treatment prevented this effect. Finally, E2 prevented FGF23-induced calcineurin activity in the heart of male mice, whereas ovariectomy triggered the development of LVH in female mice with CKD. CONCLUSIONS: We identified common molecular targets of FGF23 and E2 signaling in the heart and show that estrogen antagonizes the hypertrophic effects of FGF23, supporting female-specific cardioprotective mechanisms in CKD.
引用
- Kentrup D, Thomas JJ, Courbon G, et al. Estrogen protects female mice with chronic kidney disease from fibroblast growth factor 23-induced left ventricular hypertrophy. Kidney Int. 2026. PMID: 42055318. doi:10.1016/j.kint.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。